David A. Siegel Rocket Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 16,045 shares of RCKT stock, worth $185,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,045

Previous 28,845 44.38%

Holding current value

$185,480

Previous $621,000 52.33%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$17.6 - $25.88 $225,280 - $331,264	-12,800 Reduced 44.38%	16,045 $296,000
Q2 2024 Aug 14, 2024	SELL	$20.66 - $26.72 $1.01 Million - $1.3 Million	-48,731 Reduced 62.82%	28,845 $621,000
Q1 2024 May 15, 2024	SELL	$26.16 - $30.74 $863,280 - $1.01 Million	-33,000 Reduced 29.84%	77,576 $2.09 Million
Q4 2023 Feb 14, 2024	SELL	$16.78 - $31.94 $1.26 Million - $2.4 Million	-75,175 Reduced 40.47%	110,576 $3.31 Million
Q3 2023 Nov 14, 2023	SELL	$15.07 - $24.05 $643,489 - $1.03 Million	-42,700 Reduced 18.69%	185,751 $3.81 Million
Q2 2023 Aug 14, 2023	SELL	$16.59 - $23.6 $2.59 Million - $3.69 Million	-156,200 Reduced 40.61%	228,451 $4.54 Million
Q1 2023 May 15, 2023	SELL	$15.79 - $22.6 $997,928 - $1.43 Million	-63,200 Reduced 14.11%	384,651 $6.59 Million
Q4 2022 Feb 14, 2023	BUY	$15.5 - $22.76 $254,200 - $373,264	16,400 Added 3.8%	447,851 $8.76 Million
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $974,755 - $1.45 Million	78,800 Added 22.35%	431,451 $6.89 Million
Q2 2022 Aug 15, 2022	BUY	$7.96 - $16.64 $627,248 - $1.31 Million	78,800 Added 28.77%	352,651 $4.85 Million
Q1 2022 May 16, 2022	BUY	$13.16 - $23.68 $752,752 - $1.35 Million	57,200 Added 26.4%	273,851 $4.34 Million
Q4 2021 Feb 14, 2022	BUY	$21.52 - $36.02 $477,744 - $799,644	22,200 Added 11.42%	216,651 $4.73 Million
Q3 2021 Nov 15, 2021	BUY	$27.42 - $48.97 $504,528 - $901,048	18,400 Added 10.45%	194,451 $5.81 Million
Q2 2021 Aug 16, 2021	SELL	$39.41 - $47.25 $283,752 - $340,200	-7,200 Reduced 3.93%	176,051 $7.8 Million
Q1 2021 May 17, 2021	BUY	$43.34 - $65.91 $6.42 Million - $9.77 Million	148,175 Added 422.44%	183,251 $8.13 Million
Q4 2020 Feb 16, 2021	BUY	$23.3 - $59.57 $425,691 - $1.09 Million	18,270 Added 108.71%	35,076 $1.92 Million
Q3 2020 Nov 16, 2020	BUY	$20.5 - $28.59 $43,050 - $60,039	2,100 Added 14.28%	16,806 $384,000
Q2 2020 Aug 14, 2020	BUY	$13.32 - $22.61 $195,883 - $332,502	14,706 New	14,706 $308,000
Q4 2018 Feb 14, 2019	SELL	$11.21 - $23.53 $96,406 - $202,358	-8,600 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$18.5 - $25.49 $159,100 - $219,214	8,600 New	8,600 $212,000

Others Institutions Holding RCKT

# of Institutions

209

Shares Held

93.2M

Call Options Held

319K

Put Options Held

70.3K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $875M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account